About this episode
Alzheimer’s isn’t a sudden event. Rather, it’s a slow cascade that begins years (often decades) before symptoms present themselves. This Deep Dive explores a review positioning taurine as an early-phase, disease-modifying candidate — not as a miracle cure, but as a multi-target stabilizer that may support brain resilience upstream of major circuit loss. We break down why “single-target, late-stage” strategies struggle, how taurine may influence amyloid oligomers, mitochondrial stability, oxidative stress, calcium regulation, proteostasis/ER stress, neuroinflammation, and synaptic function, and why the real question is timing: early window vs. late-stage collapse. Promising, not proven.
(Educational content only, not medical advice.)
-
Article Discussed in Episode:
Taurine as an Early-Phase Disease-Modifying Candidate for Alzheimer’s Disease
-
Key Quotes From Dr. Mike:
“Alzheimer’s is not one pathway. It’s converging pathologies that amplify each other.”
“A multi-target molecule (i.e., taurine) isn’t a magic cure; it’s a stabilizer, especially early.”
“Energy failure isn’t a side issue. It’s part of the disease engine.”
“Neuroinflammation isn’t just a response, it can become a driver.”
“The real future is likely combination: early detection plus multi-layer neuroprotection.”
-
Key points
Alzheimer’s begins long before diagnosis; early neuroprotection may be the highest-leverage window.
Taurine is endogenous, brain-concentrated, BBB-transported, and generally well tolerated.
Alzheimer’s is a network failure (energy + inflammation + proteostasis + calcium + synapses), not one pathway.
Taurine may modulate amyloid oligomers (often more toxic than plaques) and aggregation kinetics.
Taurine is framed as a mitochondrial stabilizer (membrane potential, ATP support, less ROS signaling).
It may buffer calcium and reduce excitotoxic load while preserving physiological signaling.
It may tune ER stress / UPR and proteostasis rather than blunt adaptive stress responses.
Anti-inflammatory potential includes taurine chloramine (TauCl) as a resolution-type feedback signal.
Synaptic preservation matters more than plaque count; taurine may support plasticity markers/BDNF–CREB in models.
Clinical Alzheimer’s evidence is still limited → best framing: promising, stage-dependent, needs trials.
-
Episode timeline
